8-K: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics announces its Q4 and full year 2024 financial results, highlighting clinical trial progress and a recent financing round extending its cash runway into mid-2026.

Summary

• Tenaya Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company initiated dosing in Cohort 2 of the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy.
• Initial data from the RIDGE-1 Phase 1b clinical trial of TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy is expected in the second half of 2025.
• A recent $48.9 million financing extends the company's cash runway into mid-2026.
• As of December 31, 2024, cash, cash equivalents, and investments in marketable securities were $61.4 million, compared to $104.6 million as of December 31, 2023.
• Research and development expenses were $18.7 million for the fourth quarter and $86.7 million for the full year ended December 31, 2024.
• General and administrative expenses were $6.0 million for the fourth quarter and $29.2 million for the full year ended December 31, 2024.
• Net loss was $23.8 million, or $0.28 per share, for the fourth quarter ended December 31, 2024.
• For the full year 2024, net loss was $111.1 million, or $1.31 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical trials and has secured additional funding, but it is still operating at a loss and faces risks associated with drug development.

Positives

• Tenaya has promising early data from the first cohort of patients in the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy.
• The company's cash runway has been extended into mid-2026 due to a recent $48.9 million financing.
• Tenaya received an $8 million grant from CIRM to support the RIDGE-1 clinical trial of TN-401.
• The company obtained a new patent (617) for treating heart failure with preserved ejection fraction (HFpEF) with TN-301, providing method of treatment protection expected to expire no earlier than 2040.
• Hiro Higa has been promoted to the position of Senior Vice President, Finance and serves as the company's interim principal accounting officer.

Negatives

• The company experienced a net loss of $111.1 million for the full year 2024.
• Cash, cash equivalents, and investments decreased from $104.6 million at the end of 2023 to $61.4 million at the end of 2024.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates.
• Clinical trial results may differ from preclinical, interim, preliminary, topline or expected results.
• The company may need to raise additional funding to continue its business and product development plans.
• Tenaya relies on third parties for various aspects of its operations, which could pose risks.
• Competition in the biotechnology industry could impact Tenaya's success.

Future Outlook

Tenaya expects its current funds, including the proceeds from the recent public offering, to support planned company operations into mid-2026. The company anticipates sharing data from the MyPEAK-1 and RIDGE-1 clinical trials in 2025.

Management Comments

• Faraz Ali, Chief Executive Officer of Tenaya, stated that the company made important advances across its cardiovascular gene therapy development pipeline in 2024, positioning it for a data-rich 2025.
• He also mentioned that the recent financing allows the company to maintain its focus on driving its gene therapy programs for cardiomyopathies toward later-stage development.

Industry Context

Tenaya Therapeutics is operating in the competitive field of gene therapy for cardiovascular diseases. The company's focus on rare genetic disorders and more prevalent heart conditions aligns with the growing interest in precision medicine and targeted therapies. The progress of TN-201 and TN-401 clinical trials will be closely watched by investors and competitors in the gene therapy space.

Comparison to Industry Standards

• Tenaya's approach to gene therapy for cardiomyopathies is comparable to that of companies like Sarepta Therapeutics and Solid Biosciences, which are developing gene therapies for muscular dystrophies.
• The $48.9 million financing provides Tenaya with a runway into mid-2026, which is a critical factor for biotech companies in the clinical development stage.
• The $8 million grant from CIRM is a positive sign, as it validates the potential of Tenaya's TN-401 program and provides additional funding for clinical trials.
• The patent protection for TN-301 until at least 2040 is a significant advantage, as it provides Tenaya with exclusivity in the HFpEF market.

Management Changes

Stakeholder Impact

• Shareholders: The recent financing and clinical trial progress could positively impact shareholder value.
• Employees: The company's continued operations and clinical development efforts provide job security and opportunities for growth.
• Patients: The development of new therapies for heart disease could improve the lives of patients with these conditions.
• Suppliers: The company's operations and clinical trials create demand for goods and services from suppliers.
• Creditors: The company's financial stability and cash runway provide assurance to creditors.

Next Steps

• Tenaya plans to share data from the MyPEAK-1 and RIDGE-1 clinical trials in 2025.
• The company is on track to complete enrollment in Cohort 2 of MyPEAK-1 in the first half of 2025.
• Tenaya anticipates releasing data from its pediatric non-interventional natural history study, known as MyClimb, in the second half of 2025.
• Tenaya expects to complete enrollment of Cohort 1 of the RIDGE-1 Phase 1b clinical trial in the first half of 2025.

Key Dates